Home/Filings/4/0001213900-25-086999
4//SEC Filing

Dickey Robert IV 4

Accession 0001213900-25-086999

CIK 0001427570other

Filed

Sep 10, 8:00 PM ET

Accepted

Sep 11, 9:21 PM ET

Size

5.8 KB

Accession

0001213900-25-086999

Insider Transaction Report

Form 4
Period: 2025-08-15
Dickey Robert IV
Chief Financial Officer
Transactions
  • Award

    Common Stock

    2025-08-15+762762 total
Footnotes (1)
  • [F1]Under the terms of the Agreement and Plan of Merger, dated as of July 8, 2024, as amended (the "Merger Agreement"), by and among the Issuer, Raider Lifesciences Inc., a wholly owned subsidiary of the Issuer ("Merger Sub"), and Vyome Therapeutics, Inc. ("Vyome Therapeutics"), on August 15, 2025, Merger Sub merged with and into Vyome Therapeutics, with Vyome Therapeutics surviving the merger as a subsidiary of the Issuer (the "Merger"). Upon the closing of the Merger, each share of common and preferred stock of Vyome Therapeutics, was converted into the right to receive 1 share of the Issuer's common stock for every 5,000 shares of Vyome Therapeutics. As a result of the Merger, the Issuer was renamed "Vyome Holdings, Inc." and Vyome Therapeutics continued under its name as Vyome Therapeutics, Inc. The reporting person received 762 shares of the Issuer's common stock in exchange for 3,810,000 shares of common stock of Vyome Therapeutics pursuant to the Merger Agreement.

Documents

1 file

Issuer

Vyome Holdings, Inc

CIK 0001427570

Entity typeother

Related Parties

1
  • filerCIK 0001466862

Filing Metadata

Form type
4
Filed
Sep 10, 8:00 PM ET
Accepted
Sep 11, 9:21 PM ET
Size
5.8 KB